Articles related to OBESITY/WEIGHT MANAGEMENT

An editorial in Obesity highlights emerging evidence that GLP-1 receptor agonists may provide benefits beyond weight loss and glycemic control, while emphasizing unresolved questions regarding muscle preservation, nutritional status, and potential effects on substance use disorders.

A primary care physician describes combining nutrition counseling, individualized monitoring, and pharmacotherapy in obesity care. The interview offers a practice philosophy rather than comparative evidence supporting one treatment strategy.

Adults with type 2 diabetes initiating GLP-1 receptor agonists experienced higher rates of nonscarring alopecia than matched users of SGLT-2 or DPP-4 inhibitors. The association persisted across multiple analyses, though absolute risk remained low.

Online claims linking GLP-1 receptor agonists to increased penis size continue attracting patient attention. Available evidence suggests perceived changes may reflect weight loss and erectile function changes rather than anatomic growth.

The ACC updated its expert consensus pathway for HFpEF, emphasizing diagnostic scoring, comorbidity assessment, and newer cardiometabolic therapies. The pathway reflects emerging evidence while remaining aligned with existing heart failure guidelines.

Two prospective cohorts found that metabolically unhealthy adults generally had higher dementia risk estimates regardless of obesity status. Metabolically healthy obesity was not associated with increased dementia risk in primary analyses, though findings varied across sensitivity analyses.